文献速递冠心病外科

新一代支架与冠状动脉旁路移植术治疗无保护左主干病变的比较:值得警惕

New-generation stents compared with coronary bypass surgery for unprotected left main disease: A word of caution.
PubMed 文献 · J Thorac Cardiovasc Surg · 2018-01-12

该贝叶斯网络荟萃分析纳入9项随机对照试验,比较不同代际支架经皮冠状动脉介入治疗与冠状动脉旁路移植术治疗无保护左主干病变。结果显示,与冠状动脉旁路移植术相比,第二代药物洗脱支架与死亡/心肌梗死/卒中风险显著增加相关,而重复血运重建风险在各代支架中均较高或相当。

要点

  • 第二代药物洗脱支架与冠状动脉旁路移植术相比,死亡/心肌梗死/卒中风险显著增加(IRR 1.3,95% CrI 1.1-1.6)。
  • 裸金属支架和第一代药物洗脱支架与冠状动脉旁路移植术相比,死亡/心肌梗死/卒中风险无显著差异。
  • 重复血运重建风险以裸金属支架最高(HR 5.1,95% CI 2.1-14),第一代和第二代药物洗脱支架均为IRR 1.8。

核心结论

  • 与冠状动脉旁路移植术相比,新一代药物洗脱支架的引入并未转化为经皮冠状动脉介入治疗更好的结局。

研究设计与样本

  • 贝叶斯网络荟萃分析,纳入至少1个随机分组为支架经皮冠状动脉介入治疗或冠状动脉旁路移植术治疗左主干病变的随机对照试验。
  • 共纳入9项随机对照试验,其中6项比较经皮冠状动脉介入治疗与冠状动脉旁路移植术(n=4654),3项比较不同类型支架(n=1360)。
  • 比较裸金属支架、第一代和第二代药物洗脱支架与冠状动脉旁路移植术,随访时间6个月至5年。

主要发现

  • 与冠状动脉旁路移植术相比,第二代药物洗脱支架与死亡/心肌梗死/卒中风险显著增加相关(IRR 1.3,95% CrI 1.1-1.6)。
  • 与冠状动脉旁路移植术相比,裸金属支架(IRR 0.63,95% CrI 0.27-1.4)和第一代药物洗脱支架(IRR 0.85,95% CrI 0.65-1.1)与死亡/心肌梗死/卒中风险无显著差异。
  • 与冠状动脉旁路移植术相比,重复血运重建风险以裸金属支架最高(HR 5.1,95% CI 2.1-14),第一代药物洗脱支架(IRR 1.8,95% CI 1.4-2.4)和第二代药物洗脱支架(IRR 1.8,95% CI 1.4-2.4)相当。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: With the advent of bare metal stents and drug-eluting stents, percutaneous coronary intervention has emerged as an alternative to coronary artery bypass grafting surgery for unprotected left main disease. However, whether the evolution of stents technology has translated into better results after percutaneous coronary intervention remains unclear. We aimed to compare coronary artery bypass grafting with stents of different generations for left main disease by performing a Bayesian network meta-analysis of available randomized controlled trials. METHODS: All randomized controlled trials with at least 1 arm randomized to percutaneous coronary intervention with stents or coronary artery bypass grafting for left main disease were included. Bare metal stents and drug-eluting stents of first- and second-generation were compared with coronary artery bypass grafting. Poisson methods and Bayesian framework were used to compute the head-to-head incidence rate ratio and 95% credible intervals. Primary end points were the composite of death/myocardial infarction/stroke and repeat revascularization. RESULTS: Nine randomized controlled trials were included in the final analysis. Six trials compared percutaneous coronary intervention with coronary artery bypass grafting (n = 4654), and 3 trials compared different types of stents (n = 1360). Follow-up ranged from 6 months to 5 years. Second-generation drug-eluting stents (incidence rate ratio, 1.3; 95% credible interval, 1.1-1.6), but not bare metal stents (incidence rate ratio, 0.63; 95% credible interval, 0.27-1.4), and first-generation drug-eluting stents (incidence rate ratio, 0.85; 95% credible interval, 0.65-1.1) were associated with a significantly increased risk of death/myocardial infarction/stroke when compared with coronary artery bypass grafting. When compared with coronary artery bypass grafting, the highest risk of repeat revascularization was observed for bare metal stents (hazard ratio, 5.1; 95% confidence interval, 2.1-14), whereas first-generation drug-eluting stents (incidence rate ratio, 1.8; 95% confidence interval, 1.4-2.4) and second-generation drug-eluting stents (incidence rate ratio, 1.8; 95% confidence interval, 1.4-2.4) were comparable. CONCLUSIONS: The introduction of new-generation drug-eluting stents did not translate into better outcomes for percutaneous coronary intervention when compared with coronary artery bypass grafting.

来源:J Thorac Cardiovasc Surg,查看原文。版权归原作者所有。

引用

  1. Benedetto U, Taggart DP, Sousa-Uva M, et al. New-generation stents compared with coronary bypass surgery for unprotected left main disease: A word of caution. J Thorac Cardiovasc Surg. 2018. PMID: 29338862. doi:10.1016/j.jtcvs.2017.11.066

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。